These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29698368)

  • 21. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
    Hallmeyer S; Gonzalez R; Lawson DH; Cranmer LD; Linette GP; Puzanov I; Taback B; Cowey CL; Ribas A; Daniels GA; Moore T; Gibney GT; Tawbi H; Whitman E; Lee G; Mun Y; Liu S; Hamid O
    Melanoma Res; 2017 Dec; 27(6):585-590. PubMed ID: 29076950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
    Young K; Minchom A; Larkin J
    Future Oncol; 2012 May; 8(5):499-507. PubMed ID: 22646765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
    Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
    Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vemurafenib in melanoma with BRAF V600E mutation.
    Morita H; Nagai R
    N Engl J Med; 2011 Oct; 365(15):1448; author reply 1450. PubMed ID: 21995398
    [No Abstract]   [Full Text] [Related]  

  • 25. Vemurafenib in melanoma with BRAF V600E mutation.
    Dalle S; Poulalhon N; Thomas L
    N Engl J Med; 2011 Oct; 365(15):1448-9; author reply 1450. PubMed ID: 21995399
    [No Abstract]   [Full Text] [Related]  

  • 26. Vemurafenib in melanoma with BRAF V600E mutation.
    Lott JP
    N Engl J Med; 2011 Oct; 365(15):1449-50; author reply 1450. PubMed ID: 21995400
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA approves vemurafenib for treatment of metastatic melanoma.
    Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety of vemurafenib in patients with BRAF
    Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
    Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.
    Vanhaecke C; Deilhes F; Chanal J; Regnier-Rosencher E; Boitier F; Boulinguez S; Avril MF; Guégan S; Dupin N; Aractingi S; Meyer N; Kramkimel N
    Br J Dermatol; 2017 Oct; 177(4):e94-e95. PubMed ID: 28129668
    [No Abstract]   [Full Text] [Related]  

  • 31. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.
    Puzanov I; Amaravadi RK; McArthur GA; Flaherty KT; Chapman PB; Sosman JA; Ribas A; Shackleton M; Hwu P; Chmielowski B; Nolop KB; Lin PS; Kim KB
    Eur J Cancer; 2015 Jul; 51(11):1435-43. PubMed ID: 25980594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
    Gibney GT; Zager JS
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanisms of resistance to anti-BRAF treatments].
    Charles J; Martel C; de Fraipont F; Leccia MT; Robert C; Busser B
    Ann Dermatol Venereol; 2014 Nov; 141(11):671-81. PubMed ID: 25442471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
    Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
    Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
    Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
    J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
    [No Abstract]   [Full Text] [Related]  

  • 37. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
    Sakji-Dupré L; Le Rhun E; Templier C; Desmedt E; Blanchet B; Mortier L
    Melanoma Res; 2015 Aug; 25(4):302-5. PubMed ID: 25933211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
    Heakal Y; Kester M; Savage S
    Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.